Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immunology indications, during a ...
Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12). This is an ASCO Meeting Abstract from ...
On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant. On September ...
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...
An investigational anti-CD38 monoclonal antibody (CM313) rapidly increased platelets in immune thrombocytopenia (ITP) patients to levels sufficient for preventing bleeding, a small single-arm Chinese ...
CD38, or cyclic ADP ribose hydrolase, is a glycoprotein found on the surface of many immune cells. Binding of CD38 to its target ligand results in T cell co-stimulation, B cell maturation, and ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, ...
Oxytocin has been the focus of intense research around autism spectrum disorder (ASD) due to the hormone's reported positive effects on anxiety, empathy, social interaction, and maternal behavior. ASD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results